Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Portfolio Pulse from
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on December 10, 2024. The company, which develops cancer therapeutics using its INTASYL® siRNA gene silencing technology, will present and engage in a live Q&A session.
December 03, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals is set to present at a virtual roadshow, potentially increasing visibility and investor interest in its cancer therapeutics.
Participation in the roadshow can enhance Phio's visibility among investors, potentially leading to increased interest and positive sentiment towards the stock. The focus on their INTASYL® technology could highlight their innovative approach in cancer treatment, which may attract attention from the biotech investment community.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90